🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
0.2342
-0.0300 (-11.36%)
At close: Nov 20, 2026, 4:00 PM EST
0.238543
+0.0043 (1.85%)
After-hours: Nov 20, 2026, 7:54 PM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

LUGANO and LUCIA missed their wet AMD primary endpoint, but secondary findings supported continued focus on DURAVYU. Fully enrolled DME Phase III trials are expected to read out together in early Q4 next year, the key near-term catalyst.

Moderator

Hi, good morning, everyone. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the mid biotech analysts at UBS. Happy to introduce the team from EyePoint. We have Jay Duker, President and CEO, and also George Elston, Executive VP and CFO.

Jay Duker
President and CEO, EyePoint

Morning.

Moderator

Welcome to both of you. Thank you so much for joining us today.

Jay Duker
President and CEO, EyePoint

Thank you very much for having us.

Moderator

So maybe just to level set, you've had some key phase III readouts this year with your drug, DURAVYU. Perhaps just kind of provide a summary of where you're at the moment and what investors can look forward to.

Jay Duker
President and CEO, EyePoint

Sure. Just to give a little bit of background, DURAVYU is the vorolanib intravitreal insert. Vorolanib is a small molecule tyrosine kinase inhibitor that has activity against all the VEGF receptors, as well as PDGF and JAK1. We are studying it in two major retinal indications, wet age-related macular degeneration and diabetic macular edema. We recently reported the top line phase III results from the wet AMD trials. We did two trials. They were called LUGANO and LUCIA. Unfortunately, we didn't make the primary endpoint in either trial. The primary endpoint was non-inferiority change in visual acuity in the DURAVYU arm compared to on-label two milligram EYLEA. While the secondary endpoints in the trials, we believe were quite good, we were not non-inferior. At the present time, we have two fully enrolled diabetic macular edema trials. They're called COMO and CAPRI.

In total, they enrolled about 550 patients, and we should get the top line results in slightly under a year, early in the fourth quarter of next year. That's really the readout that I think investors should be focused on. For those who don't know the DME market, worldwide it's approximately $5 billion. In the United States, it's approximately $3 billion a year. We believe that a sustained release option like DURAVYU could be very valuable to patients and practitioners.

Moderator

Okay. Maybe we can talk about the LUCIA and LUGANO trials a little bit more, which were in wet AMD. What do you think some of the reasons are that those were unfortunately unsuccessful, and what lessons can you take from that for your DME program?

Jay Duker
President and CEO, EyePoint

That's an excellent question, obviously. Since we've gotten the results, we've put in quite a bit of effort to try to understand the results. To reiterate, our secondary endpoints in the trials were quite good. About 450 patients were treated with our drug, and we dosed it every six months. These results were with repeat dosing. We learned that the drug is quite safe. There were really no safety issues. In the retina community, in the practice of retina, the safety is really paramount. In addition, one of the things that the doctors look for is control of fluid. Fluid control is measured by optical coherence tomography, or OCT. Normal thickness of a retina in OCT is about 325 microns. Our drug controlled the fluid in the disease very well. We were only 10 microns different than the control arm.

In addition, what we are hoping to show is that we can reduce what is referred to as the treatment burden, meaning the need for injections. We did show that in both trials, that there were two fewer injections on average per year in the patients who received our drug. All of those were quite positive, and I think those have read through to diabetic macular edema, especially the fluid control and the safety. Our drug improved vision. The patients on average gained over two letters, but we were not close enough to the control arm to make the primary endpoint. Again, the essence of the question is why. What we believe is probably true is that there is a significant subgroup of patients, perhaps over 50%, who do very well with our drug.

It seems like there is another percentage of patients in whom the drug does not seem to hold their vision well enough. The evidence for that is in the patients who we refer to as the supplement-free. All of the patients in the study could have received an additional injection of EYLEA if they reached a certain amount of fluid and drop in vision. Over half the patients in both the LUGANO and LUCIA trials were supplement-free, meaning after the initial load of EYLEA, they received no other injection other than our drug. In the pooled analysis, those eyes were non-inferior to the EYLEA eyes that were supplement-free. We look at that result and we say, "Well, at least 50% of the eyes did really well with our drug alone." We are spending quite a bit of effort now to try to understand that result.

Can we identify those patients ahead of time? Conversely, can we identify the patients who did not seem to do very well visually with the drug? If we were to run another pivotal trial in wet AMD, how would we do that differently? Informing the DME trial, realistically, the DME trials were both fully enrolled prior to the top-line results. There was not going to be real large changes that we could make in the trial design, and we do not think the trial design per se led to the result that we got. On the other hand, we did make a small change in the protocol recently, which is around this criteria for supplementation. The supplementation criteria for the DME trials is now the loss of five letters over best on study, plus 50 microns of new fluid on the OCT measurement.

We have tightened up the rescue criteria, the supplement criteria, in an effort to try to hopefully stabilize the visual acuities in the patients in whom the drug is not perhaps holding the fluid.

Moderator

Okay. You mentioned considering running another phase III in wet AMD. Will you wait for the DME readout before you make that decision?

Jay Duker
President and CEO, EyePoint

Quite likely, yes. To put a little color on it, when we've spoken to retinal specialists, both community retinal specialists and KOLs, and shown them the results, and they look at those secondary endpoints, their response almost uniformly is that if this drug were approved, we would use it, even though we were not non-inferior. Because in the real world, doctors can choose to use any branded drug that they like, and therefore, if DURAVYU were approved and a patient's vision wasn't holding, if they were in that group where the drug wasn't enough to hold their vision, they could just treat them with a biologic agent. Practically speaking, the doctors were excited about the opportunity. The question is, how do we get the drug approved?

I think there's a series of events that would have to occur for us to consider doing another wet AMD trial. The first is we need to identify the patients who do well and why, and the patients who don't, in order to enrich a trial. Obviously, we need to go to the FDA and the EMA and say, "Would this trial design be acceptable, and would it be sufficient to do a third trial?" Then, of course, we need the funding for it. Right now, we're really concentrated on getting to the DME data. To answer the question quite simply, we wouldn't have any plans to do wet AMD in the near future, but with success in DME, that's something we would consider.

Moderator

It sounds like patient selection might be the most important thing in terms of

Jay Duker
President and CEO, EyePoint

We'd like to think so. Again, until we've really found definitive evidence that there are certain biomarkers or certain inclusion or exclusion criteria that would enrich the result, I'm not going to say 100%. Going back again to the results that we've seen, there does appear to be at least 50% of the enrolled eyes did very well with our drug alone.

Moderator

You mentioned your conversations with KOLs and that they would use the drug. I'm curious, where do you see the addressable population for a drug like yours, like TKI?

Jay Duker
President and CEO, EyePoint

To understand that, it's really to understand what's happening in wet AMD therapy. Wet AMD is a lifetime disease. There are very few patients who, once they start treatment, are able to stop treatment, and it's really hard to identify who they are. The assumption is if you get the diagnosis, you're going to be treated for life. On average, patients require about four to five injections a year, depending on their disease and [inaudible], and some require more. In fact, about 20% of wet AMD patients still need to be treated monthly, regardless of the agent they're being treated with. There is a very high treatment and visit burden and expense associated with wet AMD. As a result, you can imagine over time, patients miss visits, and they drop out, or they fail to see the benefit.

In fact, the evidence is about 40% of newly diagnosed wet AMD patients after 1.5 years are no longer being treated. There's a very large unmet need for agents that can prolong safely the interval between visits. Again, going back to our data, if we can identify that 50% of the wet AMD population could go every six months or longer with our drug alone, I think that would be quite a breakthrough. The second thing to remember, as I alluded to this, is this isn't an either/or situation. Almost every chronic disease one can name, there's multiple MOAs trying to address that chronic disease.

While we've started to crack that a little bit in the retina area in wet AMD with respect to, for example, blockage of ANG2 along with blockage of anti-VEGF, the biologics really are the mainstay of the therapy. The idea of using a ligand-blocking biologic in conjunction with a receptor-blocking TKI may produce synergy, and it may allow even better results in some patients. That attitude of either/or, it's one versus the other, that's never how we presented our drug. Therefore, what we're trying to do is maximize patients' vision in the long term while minimizing the need for injections.

Moderator

There's been some investor debate around the differentiation between the TKIs recently. Are you able to talk about your differentiation in terms of the TKI and the insert as well?

Jay Duker
President and CEO, EyePoint

Well, yeah, I think that that's the critical thing. I don't think you can look at a TKI in isolation, just like you can't look at the delivery system. They work together. We believe that vorolanib has significant advantages compared to the other TKIs that have been either in study or have been tried. We also believe that our delivery system is shown now to be safe and quite effective at delivering the drug. Once you've blocked a receptor and you have an insert that is releasing the drug at a slow, constant level, it's zero-order kinetics, then the receptor should remain blocked. We've got quite good PK data in humans and animals that suggests that the dose that's being released on a chronic basis from our inserts is many times above the IC50. Therefore, we're confident in the drug's ability to block the receptor.

We're confident in the biology. I think really critically is that the safety and the experience with the Durasert technology, again, there are four FDA-approved products using similar technology, and now we have this very large phase III experience. I think the safety is really a differentiating factor. One other thing that may seem perhaps not important, but from a commercial perspective may turn out to be important, is our inserts can be shipped and stored at room temperature. All the biologics need to be refrigerated, and gene therapies which are being developed generally need to be frozen. If you can imagine retinal specialist practices, they've got huge refrigerators storing multiple different biologics. If approved, we think that the ability to be stored at room temperature will be an advantage.

Moderator

Okay. Going back to your DME program, can you talk about what data you have shown so far in DME?

Jay Duker
President and CEO, EyePoint

Sure. We did a phase II study in DME called the VERONA trial, and one of the unique aspects of that trial is that was the first trial we ran in which all the patients had active disease. When we say active disease, we mean two things. They had decreased vision, and they had fluid in the retina that was attributable to the disease. The patients in that trial were all previously treated DME patients, but there was a washout period of eight weeks where they couldn't have any treatment, so they entered the study active. The simple reason we did that is DME patients over time, unlike wet AMD patients, the disease will often burn itself out, and the requirement for injections goes down.

If one were to enroll patients who didn't have active disease and the drug appeared to do well, the argument would be, well, the patient probably doesn't need treatment at all. These patients all had active disease. They were randomized into one of three arms, the higher dose of DURAVYU, which was 2.7 mg, a lower dose of 1.34 mg, or the EYLEA control. On day one, all the patients received an EYLEA injection, and 30 minutes later, they got our drug or they got a sham. One of the really important findings was as early as week four, the patients that received DURAVYU already had better vision and less fluid than the eyes that got EYLEA alone. It was about four to five letters better on the eye chart and about 40 microns less fluid.

That's an important finding, and we have set up the phase III trial to try to replicate that. Because in the end, if we are non-inferior, meaning our visual acuity results are the same as EYLEA, but we could get there faster, meaning as early as week four, we achieve better vision, less fluid, I think that would be a very strong commercial statement to make. Because if you are a patient, who wouldn't want to get better faster with fewer shots in the eye? That's an important thing that we found. In the end, the patients who in the DURAVYU arms had similar vision to the EYLEA arm, about seven letters improvement.

But if you look at the subgroup analysis, which is the patients, again, who were supplement-free, over 70% of the high-dose patients received our drug alone, and that group of patients improved 10.3 letters, and they had about 120 microns less fluid, which is really an outstanding result. Again, suggesting that there is perhaps a large subgroup of patients who can do very well with our drug. But that's, again, something where in this active group of patients, if we were able to achieve 10 letters improvement and 120 microns across the entire study, that would be a great result in the phase III. There were some secondary endpoints that we also looked at as well. For example, we looked at leakage. Leakage, again, vascular instability is a sign of inflammation, and diabetic retinopathy is notorious for that.

And in a dose-dependent fashion, compared to the beginning to the end of the trial, there was significantly less leakage in the DURAVYU eyes than in the EYLEA eyes. At the end of the trial, at 24 weeks, eyes were rated as having either no DME or still had persistent DME. Half of the patients in the DURAVYU arms had no DME anymore. None of the patients in the EYLEA arm had no DME. We have some interesting case reports of patients who were in the study in the high dose, who had been receiving anti-VEGFs going into the trial and still had active fluid, two of them including patients who had received VABYSMO, for example, and they did better with our drug, better vision and less fluid.

Well, again, it's something if we can replicate that in the real world, where the standard of care doesn't necessarily provide complete drying or better vision, but DURAVYU does, then that would be certainly a commercial advantage. So all of those results of the phase II trial give us confidence in the results of the phase III DME.

Moderator

Just remind us of the exact timelines for the phase III readouts. There's two readouts. Are they coming together or?

Jay Duker
President and CEO, EyePoint

Yes, they should be simultaneous. They started together, the two trials, and they finished enrollment within days of each other. The plan would be to release both together, and we are on track to do that early in the fourth quarter of next year. So, slightly under a year from now.

Moderator

Until then, are we going to see any additional data updates from your wet AMD trials, or are those analyses finished now?

Jay Duker
President and CEO, EyePoint

Yeah, so the wet AMD trials are both in the process of being closed, and that does take a little while. First of all, we need to follow the patients who recently received DURAVYU before we close them out. So, we are in the process of doing that. In addition, we do want to get some safety data from some of the DURAVYU-treated patients. We will have safety data of over two years, which will, if we do have a positive result at DME, we will be able to use some of that safety data in the NDA for DME to inform the safety.

If we find data that is suggestive of the subgroup analysis or inclusion/exclusion criteria, biomarkers that suggest success, I do think we will share that publicly. I do not think it is likely there will be other data readouts from wet AMD, because at this point, the studies essentially are closing.

Moderator

Okay, great. Just remind us of your cash runway as well.

Jay Duker
President and CEO, EyePoint

George?

George Elston
EVP and CFO, EyePoint

Yeah, we recently reported our Q3 results. We ended September with $118 million cash and equivalents, and our guidance was into late Q3 next year, which is close to the DME readout, and we're actively looking at several levers and options to make sure that we can get there from here, which we're pretty confident we can do through a range of reasons, operationally, to extend our cash runway to get through that important data readout.

Moderator

Great. I'm just curious, in DME, there's a large watch-and-wait segment with potentially around 40% of patients not receiving injections because it's a younger population, and there's a rebound with non-compliance. With that context, how are you thinking about the commercial opportunity? Maybe you touched on it earlier.

Jay Duker
President and CEO, EyePoint

I think the commercial opportunity from percentage-wise in DME is even better than in wet AMD for the reason you just stated. There are many patients who don't necessarily get the full treatment that they need for various reasons. One of the points you touched on is DME patients tend to be younger. Of course, they've got diabetes, so they've got multiple doctor visits. They tend to be of working age, and all of that can make it difficult to get the necessary follow-ups. The studies suggest that in the first year of DME treatment, patients should receive on average 11 injections, and in the real world in the U.S., they get about three. So, there's significant under-treatment. One of the other reasons is the perception of efficacy. It can take many injections in DME of an anti-VEGF before the patient realizes that they're actually better.

That feedback is important because if you're coming in for visits and the doctor says, "I need to do this monthly for many months," and after three or four or five injections, you're not receiving improvement, it's to receive an improvement at month one. They're much more likely to continue with treatment, especially if the treatment may be twice a year as opposed to 10 times, 11 times a year. So, the statistics that you quoted are certainly true, but a sustained release option that is equivalent to what we have now, but would enable the patients to go longer between visits and injections, would be appreciated. I'd again remind everybody, it isn't an either/or.

If doctors would use us as an underlying kind of backbone therapy, and perhaps periodically if they choose or they feel the need, use a biologic on top of it, I don't think that that approach would be problematic. While we can't prove that it's better at this point, theoretically, there may be synergy.

Moderator

Mm-hmm. Once you have the two phase III readouts in DME, what could your timelines look like? If you manage to get approved in DME but not wet AMD, or you have to wait, do you think there would be a commercial disadvantage? Because I know EYLEA HD, for example, had some difficulty getting uptake with practices because it didn't have the full label of indications.

Jay Duker
President and CEO, EyePoint

Yes, so a couple questions there. We have our own manufacturing facility. That manufacturing facility now is really ready in a sense to fully be prepared to commercialize the volume that we need of the inserts. We've been able to semi-automate or automate the process almost from start to finish. We have confidence that with approval, we would be able to supply the number of inserts that we believe commercially the need would be. So from that perspective, the timeline, again, data fourth quarter of next year, presumed approval a year later or earlier, and then we would hope to launch soon after that. That's the timelines we're currently working with. With respect to commercial, again, is it an advantage to have multiple indications? Sure it is.

But we would be able to offer something in DME that nobody else can, with the exception perhaps of intravitreal corticosteroids. Intravitreal corticosteroids have a label for every three to six months in DME, but they have significant side effects and therefore not wide use. We believe that potentially we could have similar advantages or perhaps even better vision without the cataract and that would be—

George Elston
EVP and CFO, EyePoint

[inaudible]

Jay Duker
President and CEO, EyePoint

—[inaudible] , we have that. That is already there. But the timing again, as we talked about, if we were to go back and run a third wet AMD trial, likely that trial would not be able to be started until 2028. There would be obviously then a time between launch and DME and presumed success in wet AMD.

Moderator

Great. Can you talk a little bit about the competitive landscape for this addressable population? You described the addressable population, but is it gene therapy, obviously other TKIs? Kodiak recently had some data. Can you just talk about what you see as the closest competitors?

Jay Duker
President and CEO, EyePoint

Sure. I think two things. You have to look at who is actually doing DME, and obviously we have the second-generation anti-VEGFs already available, and we have a sustained release already approved, the port delivery system, but it has not gotten a lot of commercial uptake since it is a surgical procedure. I think you also have to make a delineation between what I refer to as extended duration, like the second-generation drugs where you are giving a bolus, but they just last longer, versus true sustained release, meaning a level is achieved and that level of drug release is achieved and stays stable over many months. The competitors there would be other potential TKIs and gene therapy. When you look at DME, however, we are the only TKI in DME, and the gene therapies, one of them has just started enrolling a DME trial.

There probably will be competition, but I think if both approved, I think doctors again may prefer an option that is bioerodible and repeatable. I think the market is big enough that there is room for multiple competitors.

George Elston
EVP and CFO, EyePoint

Yeah, if I can add to that, and if you look at the specifics of vorolanib, and Jay touched on this earlier, we block both VEGF, PDGF, and IL-6, which is pretty unique to vorolanib. As you look at DME, we are addressing not just the anti-VEGF pathway, but also that inflammatory pathway. We think that is proven in the phase III going to be an important differentiator because you are taking a single molecule and treating multiple pathways, which the current biologics just do not do.

Moderator

Great. Well, I think we can probably leave it there. Thank you so much to both of you for joining us, and thank you everyone for being here.

Jay Duker
President and CEO, EyePoint

Thank you.